SHANGHAI, Sept. 10, 2021 /PRNewswire/ -- Zhongchao Inc.
(NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet
technology company offering healthcare professionals the online
healthcare information, professional training and educational
services platform and patients the patient management platform,
today announced its subsidiary Shanghai Zhongxin Medical
Technology Co., Ltd. ("Zhongxin") launches Hematological Tumor
Patient Care Center (the "Care Center"), continuing to improve its
business ecology in tumor patient management and further expanding
to out-of-hospital market. The out-of-hospital market includes
extensive online and onsite retail pharmacies and private
institutions such as private hospitals and private clinics.
The Care Center provides all-time, all-scenario, and
comprehensive out-of-hospital disease management services for
hematologic tumor patients, including 1) education and expert
lectures to strengthen patients' self-management ability, 2)
establishment of disease files, patient follow-up, periodic health
and quality-of-life assessment, medication and subsequent visit
reminder and the others to enhance patients' adherence to and
confidence in treatment, and 3) consultation hotline for immediate
information request from patients. In addition, the Care
Center provides drug assistance, pathological examination, residual
lesion examination, and genetic testing for qualified patients,
forming a service ecosystem for out-of-hospital patient
As of August 2021, Care Center has
cumulatively served nearly 10,000 patients with disease like common
hematological tumors (such as leukemia, lymphoma, and myeloma), and
rare hematological diseases (such as myelodysplastic syndrome,
myelofibrosis, Walden's macroglobulinemia, and POEMS syndrome).
More than 3,000 of physicians have provided services for patients
through the digital follow-up system on Zhongxin's platform.
Physicians can view each patient's medication records, adverse
reactions, subsequent visits, and examination results to monitor
patient's conditions and medication use and make personalized
recommendations to improve patient's mental and physical status,
patient's confidence in treatment, and treatment effectiveness and
According to Zhong Jin Qi Xin International Consulting, the
number of new cases of hematologic tumors in China is expected to reach 222,000 by 2024,
and 247,000 by 2030. Zhongchao's Care Center will be able to assist
hematological tumor patients in solving issues during treatment and
improving physical recovery. Zhongchao aims to tap the potentially
huge hematological tumor market and is always unwavering in its
commitment to improving rare disease patients' treatment experience
through its patient management services.
About Zhongchao Inc.
Incorporated in 2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is
a platform-based internet technology company. It
provides online healthcare information, professional training and
educational services to healthcare professionals under its "MDMOOC"
platform (www.mdmooc.org) and to the public under its "Sunshine
Health Forums" platform (www.ygjkclass.com) in China. Through its subsidiaries, the Company
also operates a platform offering patient management services. More
information about the Company can be found at its investor
relations website at http://izcmd.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the
Company's future business development; product and service demand
and acceptance; changes in technology; economic conditions; the
growth of the professional training and educational services market
in China and the other
international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government
regulations; fluctuations in general economic and business
conditions in China and the
international markets the Company plans to serve and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC, the length
and severity of the recent coronavirus outbreak, including its
impacts across our business and operations. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The Company
undertakes no obligation to publicly revise these forward–looking
statements to reflect events or circumstances that arise after the
For more information, please contact:
At the Company: Pei Xu, CFO
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Phone: +1 718-213-7386
SOURCE Zhongchao Inc.